Breckenridge announced it has received final approval by the Food and Drug Administration (FDA) for Repaglinide Tablets, the generic version of Novo Nordisk’s Prandin.

Prandin is a meglitinide analogue indicated as adjunct to diet and exercise in type 2 diabetes, as monotherapy or with metformin or thiazolidinediones. Prandin works by lowering blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.

RELATED: Effect of Intensive T2DM Tx Varies With Hemoglobin Glycation Index

Repaglinide Tablets will be available in 0.5mg, 1mg and 2mg strengths. Breckenridge plans to ship the product shortly.

For more information call (561) 443-3314 or visit